Home

AlzProtect is a biopharmaceutical company discovering and developing drug candidates, for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) and orphan tauopathies such as Progressive Supranuclear Palsy (PSP).

Our lead compound, AZP2006, is currently in clinical phase 1

Multiple ascending dose study in healthy volunteers is ongoing. These studies show that AZP2006 was well tolerated.

AZP2006

Read more

Targeted therapeutical areas

Read more

Alzprotect gets green light from French Regulator to start phase 2a clinical trial in Progressive...

September, 18 2019 Read more

September, 18 2019 Read more